The Inflammatory Potential of the Diet at Midlife Is Associated with Later Healthy Aging in French Adults

J Nutr. 2018 Mar 1;148(3):437-444. doi: 10.1093/jn/nxx061.

Abstract

Background: While low-grade chronic inflammation has been suggested as a major modulator of healthy aging (HA), no study has yet investigated the link between the inflammatory potential of the diet and multidimensional concepts of HA.

Objective: We aimed to evaluate the association between the inflammatory potential of the diet at midlife, as measured by the Dietary Inflammatory Index (DII), and HA assessed 13 y later.

Methods: We analyzed data from 2796 participants in the French Supplémentation en Vitamines et Minéraux Antioxydants (SU.VI.MAX) study aged 45-60 y at baseline (1994-1995) and initially free of diabetes, cardiovascular disease, and cancer. During the trial phase of the study (1994-2002), participants received either a placebo or a daily nutritional dose of antioxidant supplement (120 mg vitamin C, 6 mg β-carotene, 30 mg vitamin E, 100 μg Se, 20 mg Zn). HA was assessed in 2007-2009, and defined as having no major chronic disease, good physical and cognitive functioning, independence in daily activities, no depressive symptoms, good social health, good overall self-perceived health, and no function-limiting pain. The DII was calculated based on repeated baseline 24-h dietary records. Its association with HA was assessed by robust-error-variance Poisson regression, providing RR estimates.

Results: After adjustment for potential confounders, higher DII scores (reflecting a more proinflammatory diet), were associated with a decreased likelihood of HA: RRtertile 3/tertile 1 = 0.85 (95% CI: 0.74, 0.99); P-trend = 0.03. Secondary analyses revealed that this association was only significant among participants who had been in the placebo group during the trial phase: RRtertile 3/tertile 1 = 0.80 (95% CI: 0.64, 1.00); P-trend = 0.04.

Conclusions: This study suggests that a proinflammatory diet may lower the probability of overall HA. The SU.VI.MAX trial was registered at www.clinicaltrials.gov as NCT00272428.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living
  • Aging* / physiology
  • Aging* / psychology
  • Antioxidants / administration & dosage
  • Antioxidants / therapeutic use
  • Chronic Disease / prevention & control
  • Cognition
  • Depression / prevention & control
  • Diet*
  • Dietary Supplements
  • Feeding Behavior*
  • Female
  • France
  • Healthy Aging* / physiology
  • Healthy Aging* / psychology
  • Healthy Volunteers
  • Humans
  • Inflammation* / etiology
  • Male
  • Middle Aged
  • Pain / prevention & control
  • Social Support

Substances

  • Antioxidants

Associated data

  • ClinicalTrials.gov/NCT00272428